RSA hires Chris Molloy as chief executive
pharmafile | September 4, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Chris Molley, rsa
Life sciences executive search and interim management firm RSA has announced the appointment of Chris Molloy as its chief executive.
Molloy brings over 20 years’ experience of international life sciences to RSA across pharmaceutical, biotech and start-up sectors. He began his career with Glaxo, where he held a range of management, research, business change and scientific collaboration roles.
Moving to Asia in 2004 Molloy became COO of the award-winning emerging biotech firm MerLion Pharmaceuticals, where he was also responsible for fundraising and business development.
Most recently he has been VP Corporate Development and Marketing at IDBS. In addition to a range of technology development and biotech advisory roles, Molloy has also been a non-executive member of the RSA Board since 2009. He will retain his active scientific role in the pre-clinical development and licensing of new medicines for HIV with KFLP Biotech, a ‘virtual’ US R&D company.
“I am delighted to be joining the executive team at RSA,” said Molloy. “The life sciences industry is undergoing seismic change: one in which high quality people are the key asset for success. I have enjoyed working with Nick Stephens and the Board over the past four years and I look forward to helping RSA continue to thrive.”
Nick Stephens who is the executive chairman at RSA, said: “The time has come to prepare for the next step in our evolution. We are excited to have Chris on board as RSA’s chief executive. He will continue to preserve the special culture and feel of RSA whilst making ourselves even more professional as an executive search and interim business.”
Related Content
Hold your horses: M&A is about talent, not just pipelines
The morning mist is rising on the battlefield. At stake: the crown riches and glory …
Addressing the boardroom gender gap
The issue of gender balance within UK boards has moved quickly up the business agenda …
UK pharma downbeat on its future – survey
The impacts of NHS reform and the increasingly high cost of R&D is causing pharma …
